Sangamo is pioneering the future of genomic medicine
Sangamo Therapeutics is a genomic medicine company dedicated to translating groundbreaking science into medicines that transform the lives of patients and families afflicted with serious neurological disease. Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from diseases for which today’s medicine can only offer symptom management at best.
Minimum 15 minutes delayed. Source:
-
November 4, 2024
RICHMOND, Calif. --(BUSINESS WIRE)--Nov. 4, 2024-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its third quarter 2024 financial results after the market close on Tuesday, November 12, 2024 .
-
October 22, 2024
- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by
-
August 6, 2024
Announced global epigenetic regulation and capsid delivery license agreement with Genentech to develop novel genomic medicines for neurodegenerative diseases. Expect to receive $50 million in near-term upfront license fees and milestone payments and eligible to earn up to $1.9 billion in milestone
-
August 6, 2024
Agreement leverages Sangamo’s proprietary capsid delivery platform and epigenetic regulation capabilities to address certain neurodegenerative diseases Sangamo expected to receive $50 million in near-term upfront license fees and milestone payments and is eligible to earn up to $1.9 billion in
| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| SC 13G/A | An amendment to the SC 13G filing |
Other
|
View HTML | |
| 3 | Initial filing by director officer or owner of more than ten percent |
3,4,5
|
View HTML | |
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA |
-
Nov 12, 2024 at 4:30 PM EST
-
Sep 9, 2024 at 8:00 AM EDT
-
Sep 6, 2024 at 12:00 PM EDT